Abstract
Ischemic stroke is a leading cause of mortality worldwide with limited treatment options. Since its pathophysiology involves free radical production, excitotoxicity, and stimulated inflammatory processes, therapeutic agents that can counter oxidative stress and associated inflammation could provide neuroprotection in the advent of cerebral stroke. Many natural agents have shown promise to provide protection in ischemia but often fail clinically due to degradation, poor aqueous solubility, and bioavailability. The therapy here aims at overcoming demerits and delivering these neuroprotectants in a controlled site-specific mechanism via nanoparticles. A nanoparticulate drug delivery system is a nanosized formulation that enables the introduction of an active into the body and positively modifies its therapeutic outcome by controlling its rate, time, and site of release. Lipid nanoparticles (LNs) (SLNs, liposomes, lipid drug conjugates, etc.) are popular delivery systems due to biocompatibility, reduced toxicity, and versatility, thus making them promising candidates for the drug development.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
